Skip to main content
OpenTrials
Completed

NCT Number: NCT03940664

CD160 Expression in Retinal Vessels is Associated With Retinal Neovascular Diseases

The aims of this study were

* to analyze CD160 expression in both normal and pathological eyes from human adults * to evaluate association between CD160 presence on endothelial cells from blood vessels and retinal vascular disease

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Surgical Retinal

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Chu Reims

France, Reims, 51092

About this study

Anti-angiogenic agents stand first in the treatment of neovascular diseases of the retina. Intravitreal injections of anti-Vascular Endothelial Growth Factor (VEGF) agents have emerged over the past decade as the first line of treatment in some neovascular diseases of the retina. Nevertheless, anti-VEGF therapies suffer some limitations, among which a short time to recurrence (1 week to 3 months) of retinal neovascularization and an eroding biological effect after prolonged use and.

CD160 appeared in several experimental studies as a marker of activated endothelial cells, suggesting it could represent a promising target for novel anti-angiogenic.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with retinal surgery
  • Patients who agree to participate to the study
  • Major patient

Exclusion criteria

  • Patient under law protection
  • Minor patient

Treatment and study plan

immunohistochemistry on Formalin fixed and paraffin embedded blocks

Other

Primary outcomes

  1. CD160 staining intensity score

    Time frame: Day0

    Formalin fixed and paraffin embedded blocks were used for immunohistochemistry using CD160.

    The immunolabelling was evaluated independently by 2 observers (CBR, AH) blinded to clinical data. The staining intensity (0: absent, 1: faint, 2: moderate, 3: strong) was assessed for CD160 immunolabelling.

Secondary outcomes

  1. CD105 staining intensity score

    Time frame: Day0

    Formalin fixed and paraffin embedded blocks were used for immunohistochemistry using CD105.

    The immunolabelling was evaluated independently by 2 observers (CBR, AH) blinded to clinical data. The staining intensity (0: absent, 1: faint, 2: moderate, 3: strong) was assessed for CD105 immunolabelling.

Sponsors and collaborators

Lead sponsor

CHU de Reims

Other

Registry information

Acronym: NEOVASC-CD160

Important dates

Study start
2008
Primary completion
2017
Study completion
2017
First posted
May 7, 2019
Registry last updated
May 7, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.